Helsinn and Vifor Pharma sign Licensing and Distribution agreement for Netupitant-Palonosetron fixed dose combination
Lugano/Glattbrugg, Switzerland (ots) - Helsinn Healthcare SA and Vifor Pharma, announced that the companies have entered into an exclusive license and distribution agreement for netupitant-palonosetron fixed dose combination, a Helsinn product currently in the development stage for the treatment of ...
mehr